HENDERSON, Nev.--(BUSINESS WIRE)--Nov. 13, 2018--
Spectrum Pharmaceuticals Inc., (NASDAQ: SPPI) a biotechnology
company with fully integrated commercial and drug development operations
and a primary focus in hematology and oncology, today announced the
appointment of Jeffrey Vacirca, MD, FACP to its Board of Directors.
Dr. Vacirca is a practicing oncologist and the current president of the
Community Oncology Alliance, an advocacy group focused on supporting
community oncology clinics. Additionally, Dr. Vacirca is the medical
director of the nation’s largest community oncology group purchasing
organization, International Oncology Network and the CEO and managing
partner at North Shore Hematology Oncology Associates. He also serves as
the vice chairman at Odonate Therapeutics (NASDAQ: ODT), an oncology
company focused on treating metastatic breast cancer. Furthermore, he
has joined the Board of Directors for One Oncology, an oncologist-led
company providing oncologists with innovative tools to help keep cancer
care in the hands of the providers.
“As a prominent leader within community oncology, Dr. Vacirca has a
reputation and clear understanding of how to successfully develop and
commercialize oncology pharmaceuticals,” said Joe Turgeon, President and
Chief Executive Officer of Spectrum Pharmaceuticals. “His expertise
working across multiple stakeholders including patient advocacy groups,
clinical investigators, group purchasing organizations, and government
agencies is invaluable and precisely what is needed as Spectrum advances
its two late-stage pipeline products, poziotinib and ROLONTIS.”
“Joining the Spectrum Board provides me the rare opportunity to fulfill
a passion for patient care while working with a company developing life
changing therapies,” said Dr. Vacirca. “Poziotinib has the potential to
change the treatment paradigm for a subset of cancer patients that have
had no adequate treatment options. Additionally, Spectrum has developed
a novel G-CSF, which is the first new drug in over fifteen years for use
in chemotherapy induced neutropenia.”
With Dr. Vacirca’s appointment, the Spectrum Board increases to nine
directors, each of whom are nominated annually by the nominating and
corporate governance committee.
About the Spectrum’s Late-Stage Pipeline
Spectrum Pharmaceuticals has two promising late-stage therapies
including poziotinib, an investigational therapy targeting the exon 20
insertion mutation. There are currently no FDA approved targeted
therapies for the exon 20 mutation. Poziotinib is currently being
studied in a pivotal, multicenter Phase 2 trial for non-small cell lung
cancer for patients with the exon 20 mutation. Recent data from an MD
Anderson Phase 2 study of poziotinib demonstrated strong efficacy in
metastatic, heavily pretreated EGFR and HER2 exon 20 mutant NSCLC
patients. The second late-stage pipeline product, ROLONTIS®
(eflapegrastim), is a novel G-CSF therapy being investigated for use in
chemotherapy induced neutropenia. Spectrum Pharmaceuticals plans to file
a BLA submission with the FDA for ROLONTIS by the end of 2018.
About Spectrum Pharmaceuticals, Inc.
Spectrum Pharmaceuticals is a leading biotechnology company focused on
acquiring, developing, and commercializing drug products, with a primary
focus in hematology and oncology. Spectrum currently markets six
hematology/oncology drugs and has an advanced stage pipeline that has
the potential to transform the company. Spectrum's strong track record
for in-licensing and acquiring differentiated drugs, and expertise in
clinical development have generated a robust, diversified, and growing
pipeline of product candidates in advanced-stage Phase 2 and Phase 3
studies. More information on Spectrum is available at www.sppirx.com.
Forward-looking statement — This press release may contain
forward-looking statements regarding future events and the future
performance of Spectrum Pharmaceuticals that involve risks and
uncertainties that could cause actual results to differ materially.
These statements are based on management's current beliefs and
expectations. These statements include, but are not limited to,
statements that relate to Spectrum’s business and its future, including
certain company milestones, Spectrum's ability to identify, acquire,
develop and commercialize a broad and diverse pipeline of late-stage
clinical and commercial products, the timing and results of FDA
decisions, and any statements that relate to the intent, belief, plans
or expectations of Spectrum or its management, or that are not a
statement of historical fact. Risks that could cause actual results to
differ include the possibility that Spectrum’s existing and new drug
candidates may not prove safe or effective, the possibility that our
existing and new applications to the FDA and other regulatory agencies
may not receive approval in a timely manner or at all, the possibility
that our existing and new drug candidates, if approved, may not be more
effective, safer or more cost efficient than competing drugs, the
possibility that our efforts to acquire or in-license and develop
additional drug candidates may fail, our dependence on third parties for
clinical trials, manufacturing, distribution and quality control and
other risks that are described in further detail in the company's
reports filed with the Securities and Exchange Commission. The company
does not plan to update any such forward-looking statements and
expressly disclaims any duty to update the information contained in this
press release except as required by law.
SPECTRUM PHARMACEUTICALS, INC.® and ROLONTIS® are
registered trademarks of Spectrum Pharmaceuticals, Inc and its
affiliate. REDEFINING CANCER CARE™ and the Spectrum Pharmaceuticals
logos are trademarks owned by Spectrum Pharmaceuticals, Inc. Any other
trademarks are the property of their respective owners.
© 2018 Spectrum Pharmaceuticals, Inc. All Rights Reserved
View source version on businesswire.com: https://www.businesswire.com/news/home/20181113005325/en/
Source: Spectrum Pharmaceuticals Inc.
Spectrum Pharmaceuticals Inc.
Shiv Kapoor, 702-835-6300
Vice
President, Strategic Planning & Investor Relations
InvestorRelations@sppirx.com
